Recent studies have shown that inhibition of IRAK1 could ameliorate IKBα phosphorylation, which in turn inhibits NF-κB signaling and downstream proinflammatory cytokine production in immunocompetent cells, reducing lupus-related renal damage. Here, NFKB1 is linked to systemic lupus erythematosus.